BridgeBio Pharma BBIO Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating lease liabilities (total)?
- BridgeBio Pharma (BBIO) reported operating lease liabilities (total) of $18.66M in Q1 2026.
- How has BridgeBio Pharma's operating lease liabilities (total) changed year-over-year?
- BridgeBio Pharma's operating lease liabilities (total) increased by 84.3% year-over-year, from $10.12M to $18.66M.
- What is the long-term trend for BridgeBio Pharma's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities (total) has grown at a -11.5% compound annual growth rate (CAGR), from $18.47M to $10M.
- What does operating lease liabilities (total) mean?
- The total financial obligation for long-term leases of property and equipment.
- How do you interpret operating lease liabilities (total)?
- An increase indicates expansion of physical footprint or equipment leasing, which raises fixed costs, while a decrease suggests lease expirations or reduced facility requirements.
- How does operating lease liabilities (total) compare across companies?
- Highly comparable across biotech firms, as most companies lease specialized laboratory and office space rather than owning real estate outright.